Qbrexza (Glycopyrronium Tosylate) Patent Expiration, LOE Window & CMS Spending

Qbrexza (Glycopyrronium Tosylate) by Journey Medical: FDA Orange Book core substance LOE 2033-02-28, 0 AB generics, $2.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJourney Medical
FDA Application & PathwayN210361 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-02-28
Last Listed Patent or Exclusivity Date2033-02-28
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.0M
2024 Medicare Part D Spend$2.0M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel